Incyte Corporation (INCY): Price and Financial Metrics

Incyte Corporation (INCY)

Today's Latest Price: $87.76 USD

2.87 (-3.17%)

Updated Oct 19 9:50pm

Add INCY to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

INCY Stock Summary

  • INCY has a market capitalization of $19,820,698,074 -- more than approximately 90.31% of US stocks.
  • Of note is the ratio of Incyte Corp's sales and general administrative expense to its total operating expenses; only 9.46% of US stocks have a lower such ratio.
  • For INCY, its debt to operating expenses ratio is greater than that reported by merely 5.85% of US equities we're observing.
  • If you're looking for stocks that are quantitatively similar to Incyte Corp, a group of peers worth examining would be BNTX, MGNX, MCRB, NTLA, and XENE.
  • Visit INCY's SEC page to see the company's official filings. To visit the company's web site, go to

INCY Stock Price Chart Interactive Chart >

Price chart for INCY

INCY Price/Volume Stats

Current price $87.76 52-week high $110.36
Prev. close $90.63 52-week low $62.48
Day low $86.90 Volume 1,037,300
Day high $91.29 Avg. volume 1,605,645
50-day MA $91.92 Dividend yield N/A
200-day MA $89.83 Market Cap 19.19B

Incyte Corporation (INCY) Company Bio

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company was founded in 1991 and is based in Wilmington, Delaware.

INCY Latest News Stream

Event/Time News Detail
Loading, please wait...

INCY Latest Social Stream

Loading social stream, please wait...

View Full INCY Social Stream

Latest INCY News From Around the Web

Below are the latest news stories about Incyte Corp that investors may wish to consider to help them evaluate INCY as an investment opportunity.

Incyte PD-1 inhibitor shows benefit in mid-stage anal cancer study

A 94-subject Phase 2 clinical trial, PODIUM-202, evaluating Incyte's (INCY) PD-1 inhibitor retifanlimab (formerly INCMGA0012) in previously treated patients with advanced squamous cell carcinoma of the anal canal ((SCAC)) who have progressed after platinum-based chemo showed a treatment benefit. The results are available on demand at ESMO.The overall response rate...

Seeking Alpha | September 18, 2020

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

WILMINGTON, Del.--(BUSINESS WIRE)--Encouraging Results from Phase 2 Trial of Retifanlimab in Patients with Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

Business Wire | September 18, 2020

Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas

Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas

Business Wire | September 17, 2020

Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

INDIANAPOLIS, Sept. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the…

PR Newswire | September 14, 2020

Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that was created to support people living with graft-versus-host disease (GVHD) by encouraging innovative and novel solutions that address specific challenges facing the GVHD community. Massachusetts General Cancer Center has been awarded $100,000 to implement its project, Horizon Mobile App for Patients with Chr

Business Wire | September 9, 2020

Read More 'INCY' Stories Here

INCY Price Returns

1-mo 1.12%
3-mo -17.71%
6-mo -13.08%
1-year 12.86%
3-year -23.15%
5-year -18.10%
YTD 0.50%
2019 37.32%
2018 -32.86%
2017 -5.55%
2016 -7.54%
2015 48.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7977 seconds.